Abstract

19-Nortestosterone C-17 epimers with prominent antiproliferative properties have been previously described. In our present study, five novel 17α-19-nortestosterones (3−7) were synthesized to increase their beneficial biological activities with no associated undesired hormonal effects. The compounds were screened by a viability assay against a panel of human adherent gynecological cancer cell lines. Three of the tested derivatives (3−5) exhibited a remarkable inhibitory effect on the proliferation of HeLa cells with IC50 values lower than that of our reference agent cisplatin (CIS). These three active agents also displayed considerable cancer selectivity as evidenced by their weaker growth inhibitory effect on non-cancerous fibroblast cells compared to CIS. The most potent newly synthesized 17α-chloro derivative (3) was selected for additional experiments in order to characterize its mechanism of action. Since nandrolone (19-nortestosterone, 1) is a structural analog with selective antiproliferative action on cervical carcinoma cells, it was utilized as a positive control in these studies. A lactate dehydrogenase (LDH) assay demonstrated a moderate cytotoxic effect of the test compounds. Cell cycle disturbance and the elevation of the hypodiploid population elicited by the test agents were detected by flow cytometry following propidium staining. The proapoptotic effects of the tested steroids were confirmed by fluorescent microscopy and a caspase-3 activity assay. Treatment-related caspase-9 activation without a substantial change in caspase-8 activity indicates the induction of the intrinsic apoptotic pathway. The selected agents directly influence the rate of tubulin assembly as evidenced by a polymerization assay. Yeast-based reporter gene assay revealed that the androgenic activity of the novel 19-nortestosterone derivative 3 is by multiple orders of magnitude weaker than that of the reference agent 1. Based on the behavior of the examined compounds it can be concluded that a halogen substitution of the 19-nortestosterone scaffold at the 17α position may produce compounds with unique biological activities. The results of the present study support that structurally modified steroids with negligible hormonal activity are a promising basis for the research and development of novel anticancer agents.

Highlights

  • Cancer is the second leading cause of death globally: in 2015 malignancies were responsible for 8.7 million deaths, and 17.5 million new cancer cases were registered worldwide

  • The exact conditions applied for the preparation processes of the synthesized 19-nortestosterone analogs 2–7 and their detailed characterization are provided as Supplementary Material. 10 mM stock solutions of the tested agents were prepared with dimethyl sulfoxide (DMSO) for all in vitro experiments

  • Various biological effects of compounds with an androstane skeleton mostly stem from their endocrine disruptor properties, the medical use of androgens is mainly limited to androgen replacement and androgen deprivation therapies, including the management of some hormone dependent malignancies (Wadosky and Koochekpour, 2016)

Read more

Summary

Introduction

Cancer is the second leading cause of death globally: in 2015 malignancies were responsible for 8.7 million deaths, and 17.5 million new cancer cases were registered worldwide. Based on incidence estimates the number of new cases is expected to rise by about 70% over the two decades (Fitzmaurice et al, 2017). Besides numerous preventive strategies and early diagnosis, the research for and development of innovative anticancer agents is one of the most important approaches to decrease global cancer burden. Steroidal agents used in oncological practice are typically administered for their endocrine disruptor properties (e.g., estrogen antagonists, aromatase inhibitors). Besides the well-known endocrine disruptors several other steroids have been reported to exert pronounced anticancer effects in a hormone-independent manner. It is demonstrated to induce programmed cell death in endothelial cells and suppresses cancer-related angiogenesis (Yue et al, 1997; LaVallee et al, 2002)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call